

**Wanbury Limited**

Regd. Office : BSEL Tech Park, B-wing
10th Floor, Sector-30 A,
Opp. Vashi Railway Station,
Vashi Navi Mumbai 400 703
Maharashtra, INDIA
Tel : +91-22-6794 2222
+91-22-7196 3222
CIN L51900MH1988PLC048455
Email : info@wanbury.com
Website : www.wanbury.com

August 4, 2025

To, The Manager - Listing Department, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 524212	To, The Manager - Listing Department, National Stock Exchange of India Ltd., Exchange Plaza, Plot No. C/1, G - Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400 051. Scrip Symbol: WANBURY
---	--

Dear Sir / Madam,

Sub.: Outcome of the Board Meeting held on August 4, 2025

This is with reference to the above mentioned subject, we would like to inform you that the Board of Directors of the Company at its meeting held today i.e. **Monday, August 4, 2025** has considered and approved the Un-audited Financial Results (Standalone & Consolidated) of the Company for the first quarter and three months ended 30th June, 2025. The results will be uploaded on the website (www.wanbury.com). Further, as per Regulation 33, Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we are enclosing herewith the following:

- Un-audited Financial Results (Standalone & Consolidated) of the Company for the first quarter and three months ended 30th June, 2025 alongwith Limited Review Report.
- In terms of provisions of Regulation 30 of the SEBI (LODR) Regulations, 2015 read with relevant provisions of SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (collectively referred to as "SEBI Circulars"), issued by the Securities and Exchange Board of India, we wish to inform you that grant of 91,500 stock options (ESOPs) to employee/s of the Company as approved by the Nomination and Remuneration Committee ("NRC") and Board of Directors of the Company under Wanbury Limited Employee Stock Option Plan 2016 ("WANBURY ESOP 2016") and in this regard, we enclose the general terms and conditions details of the said grant, as necessitated vide SEBI Circulars as 'ANNEXURE - A'.
- Based on recommendation of Nomination, Remuneration Committee, the Board has considered and approved the re-appointment of Mr. Chandran Krishnamoorthy (DIN - 00005868) as Whole Time Director of the Company to hold office for a term of five (5) years, with effect from 18th September, 2025, in terms of the Companies Act, 2013 read with the Rules made thereunder and the SEBI Listing Regulations, subject to the approval of the Members of the Company by way of special resolution and such regulatory/ statutory authorities as may be applicable. The brief profile along with relevant disclosures of Mr. Chandran Krishnamoorthy (DIN - 00005868) are enclosed herewith as 'ANNEXURE - B'.





- d) Initiation of closure of 3 (three) foreign subsidiaries including step-down subsidiary incorporated in Netherlands, China and UAE. The said subsidiaries had not commenced any business or conducted any operations or activities since the date of its incorporation.


Please note that the closure of the subsidiaries will not affect the revenue or business of the Company as the subsidiaries had not commenced any business since the date of its incorporation.

Further, the requisite details as necessitated vide SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated 11 November, 2024 as 'ANNEXURE - C'.

The Meeting of the Board of Directors commenced at 11:00 A.M. and concluded at 08:30 P.M. We request you to take this information on your records.

Thanking you,

Yours truly,
For Wanbury Limited


Jitendra J. Gandhi
Company Secretary



Encl.: a/a.

ANNEXURE - A

Disclosures about Options to purchase securities including, Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ("SEBI SBEB Regulations, 2021") at the time of instituting the scheme and vesting or exercise of options and Disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are as under:

Sr. No.	Disclosures	Particulars
a)	Brief details of options granted	91,500 stock options (ESOP's) granted to eligible employees of the Company. Each option upon exercise would be entitled for allotment of one equity share of Rs. 10/- each of the Company.
b)	Whether the scheme is in terms of SEBI SBEB Regulations, 2021 (if applicable)	Yes, the WANBURY ESOP 2016 is in terms of SEBI SBEB Regulations, 2021.
c)	Total number of shares covered by these options	91,500 equity shares of Rs 10/- each of the Company.
d)	Pricing formula	Rs. 10/- (Rupees Ten only) per option upon exercise of stock option
e)	Options Vested: Options granted under Wanbury ESOP 2016 would vest not earlier than one year and not later than two years from the date of grant of such options. As decided by the Nomination & Remuneration Committee, the following is the vesting schedule for 91,500 stock options : Part A (40% of total grant of stock options) - Loyalty : 36,600 options and Part B (60% of total grant of stock options) - Performance : 54,900 options granted to eligible employees of the Company: <ul style="list-style-type: none"> At the end of the 1st year from the Grant date - 40% of Part A and Part B At the end of the 2nd year from the Grant date - 60% of Part A and Part B 	
f)	Time within which options may be exercised	The vested options are exercisable within a period of 2 (two) years from the date of vesting of the options.
g)	Options exercised	N.A.
h)	Money realized by exercise of Options	N.A.
i)	The total number of shares arising as a result of exercise of option	N.A.
j)	Options lapsed	N.A.
k)	Variation of terms of options	N.A.
l)	Brief details of significant terms	N.A.
m)	Subsequent changes or cancellation or exercise of such options	N.A.
n)	Diluted earnings per share pursuant to issue of equity shares on exercise of options	N.A.



ANNEXURE - B

Disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Paragraph A of Part A of Schedule III and SEBI Master Circular No. SEBI/ HO/CFD/ PoD2/CIR/ P/0155 dated November 11, 2024 concerning the appointment of Mr. Chandran Krishnamoorthy (DIN - 00005868) as Whole-time Director:

Disclosure requirements	Details
Reason for change	Re-Appointment as a Whole-time for a period 5 (five) years.
Date of Appointment and Terms of Appointment	Subject to approval of shareholders, Mr. Chandran Krishnamoorthy (DIN - 00005868), has been appointed as a Whole Time Director of the Company to hold office for a term of five years with effect from 18 th September 2025, upon such terms & conditions (including remuneration, if any) as may be determined by the Board from time to time within the overall limits as detailed in the explanatory statement to his appointment, if any, under the Companies Act, 2013 and applicable law. He shall hold the office for a period of five years.
Brief Profile	Mr. Chandran Krishnamoorthy (DIN: 00005868) is a highly experienced professional with over three decades of expertise in corporate leadership and governance. He has been associated with Wanbury Limited since 2010. Under his leadership, the Company has made significant progress in strengthening its presence in the pharmaceutical sector, with a focus on operational excellence and strategic expansion. Mr. Krishnamoorthy brings deep industry insight and a results-driven approach to the Board. His strong business acumen and commitment to high standards of compliance have been instrumental in guiding the Company through various phases of growth and transformation. He has played a key role in enhancing stakeholder value and ensuring sound corporate governance practices. His contributions to board discussions and decision-making reflect his dedication and forward-thinking mindset. Mr. Krishnamoorthy continues to provide valuable leadership to Wanbury Limited in its journey of sustainable growth.
Disclosure of Relationship between Directors	Mr. Chandran Krishnamoorthy (DIN - 00005868) is not related to any of the Directors of the Company.
Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Ltd. With ref. no. NSE/CML/2018/24, both dated 20th June, 2018.	Mr. Chandran Krishnamoorthy (DIN - 00005868) is not debarred from holding the office of director by virtue of any order of SEBI or any other authority. The same is also verified by the Nomination and Remuneration Committee of Company.



ANNEXURE-C

Disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/ HO/CFD/ PoD2/CIR/ P/0155 dated November 11, 2024 concerning initiation of closure of foreign subsidiaries.

Particulars	Details
The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year	<p>The below mentioned Subsidiaries had not commenced any business or conducted any operations or activities since the date of its incorporation.</p> <ol style="list-style-type: none"> 1. Ningxia Wanbury Fine Chemicals Co., Ltd 2. Wanbury Holdings B.V. 3. Wanbury Global FZE <p>Accordingly, the turnover or revenue or income and net worth of the said Subsidiaries is Nil for the Financial Year 2024-25</p>
Date on which the agreement for sale has been entered into	Not Applicable
The expected date of completion of sale/disposal	Not Applicable.
Consideration received from such sale/disposal	Not Applicable
Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof	Not Applicable
Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arms length"	Not Applicable
Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same are including compliance with regulation 37A of LODR Regulations.	Not Applicable
In case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale	Not Applicable





KAPOOR & PAREKH ASSOCIATES
CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on Review of Interim Standalone Financial Results

To The Board of Directors of Wanbury Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of **WANBURY LIMITED** ("the Company") for the quarter ended 30 June 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial reporting" ("Ind-AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable Indian Accounting Standards and other recognised accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. Other Matters:
 - 5.1 Attention is drawn to the fact that the figures for the quarter ended 31 March 2025 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of the previous financial year had only been reviewed and not subjected to audit.





KAPOOR & PAREKH ASSOCIATES
CHARTERED ACCOUNTANTS

5.2 We have not reviewed the comparative standalone financial information appearing in the statement of the corresponding quarter ended 30 June 2024.

The standalone financial information of the Company for the corresponding quarter ended 30 June 2024 were reviewed by previous statutory auditors who issued their unmodified conclusion, vide their report dated 12 August 2024.

Our conclusion is not modified in respect of matters specified in paragraph 5 above.

For Kapoor & Parekh Associates
Chartered Accountants
ICAI FRN 104803W

ARKU

Ankit Parekh
Partner

M. No. 160398

UDIN: 25160398 8M0U2P3439



Mumbai, 04 August 2025



Wanbury Limited

Regd. Office : BSEL Tech Park, B-wing
10th Floor, Sector-30 A,
Opp. Vashi Railway Station,
Vashi Navi Mumbai 400 703
Maharashtra, INDIA
Tel : +91-22-6794 2222
+91-22-7196 3222
CIN L51900MH1988PLC048455
Email : info@wanbury.com
Website : www.wanbury.com

WANBURY LIMITED					
Statement of Unaudited Standalone Financial Results for the Quarter ended 30 June 2025					
₹ in Lakhs					
Sr. No.	Particulars	Quarter ended			Year ended
		30/06/2025	31/03/2025	30/06/2024	31/03/2025
		Unaudited	Audited	Unaudited	Audited
1	Income:				
	(a) Revenue from operations	16,318.40	17,199.95	13,110.82	59,951.42
	(b) Other income	34.79	184.43	94.46	349.33
	Total Income	16,353.19	17,384.38	13,205.28	60,300.75
2	Expenses:				
	(a) Cost of materials consumed	7,278.41	7,594.54	6,419.91	27,788.20
	(b) Purchase of stock-in-trade	309.73	389.35	327.55	1,507.59
	(c) Changes in inventories of finished goods, stock in trade and work-in-progress	(53.58)	448.11	(121.98)	151.14
	(d) Employee benefits expense	2,868.64	2,642.14	2,515.16	10,423.76
	(e) Finance costs	754.03	904.24	759.26	3,695.07
	(f) Depreciation and amortisation expense	364.37	337.42	328.87	1,331.11
	(g) Other expenses	3,471.01	3,163.17	2,872.77	12,448.81
	Total Expenses	14,992.61	15,478.97	13,101.54	57,345.68
3	Profit before tax	1,360.58	1,905.41	103.74	2,955.07
4	Tax expenses:				
	(a) Current Tax	-	586.09	-	586.09
	(b) Deferred Tax (Net)	11.53	(706.33)	-	(684.03)
5	Profit after tax	1,349.05	2,025.64	103.74	3,053.01
6	Other comprehensive Income / (Loss)				
	Items that will not be reclassified to profit or loss				
	- Actuarial gain/ loss on defined benefit obligation	(24.30)	8.97	(27.26)	(54.84)
	Income tax effect on above	8.49	(3.14)	-	19.16
	Items that will be reclassified subsequently to profit or loss				
	- The effective portion of gain and losses on hedging instruments in a cash flow hedge.	(8.70)	(1.80)	-	(1.80)
	Income tax effect on above	3.04	0.63	-	0.63
	Other comprehensive Income / (Loss) net of tax	(21.47)	4.66	(27.26)	(36.85)
7	Total comprehensive Income	1,327.58	2,030.30	76.48	3,016.16
8	Paid up Equity Share Capital (Face Value of ₹ 10 each)	3,287.70	3,277.05	3,274.55	3,277.05
9	Other equity				2,650.13
10	Earnings per share of ₹10 each(not annualised for the quarter)				
	(1) Basic - ₹	4.12	6.18	0.32	9.32
	(2) Diluted - ₹	3.95	5.98	0.31	8.98

See accompanying notes to the financial results





Wanbury Limited

Regd. Office : BSEL Tech Park, B-wing
10th Floor, Sector-30 A,
Opp. Vashi Railway Station,
Vashi Navi Mumbai 400 703
Maharashtra, INDIA
Tel. : +91-22-6794 2222
+91-22-7196 3222
CIN L51900MH1988PLC048455
Email : info@wanbury.com
Website : www.wanbury.com

Wanbury Limited

Statement of Unaudited Standalone Financial Results for the quarter ended 30 June 2025

Notes :-

- 1) The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on 4 August 2025.
- 2) These results are prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind 34") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles, practices and policies generally accepted in India.
- 3) The Company has only one segment of activity namely "Pharmaceuticals".
- 4) The Company has two USFDA approved manufacturing facilities at Tanuku, Andhra Pradesh and Patalganga, Maharashtra.
- 5) During the quarter 1,06,500 equity shares of ₹ 10 each fully paid up, were allotted upon exercise of vested options pursuant to the "Wanbury ESOP-2016", resulting in an increase in the paid-up share capital by ₹ 10.65 Lakhs and Securities Premium account by ₹ 144.31 Lakhs.
- 6) The figures for the fourth quarter ended 31 March 2025 in the above financial result are the balancing figures between audited figures for the full financial year and year to date unaudited figures published up to nine months ended 31 December 2024 which were subjected to limited review.
- 7) The figures of previous periods/year have been re-grouped / re-classified wherever necessary, to correspond with figures of current period.

Place : Mumbai
Date : 4 August 2025

For Wanbury Ltd.

R. Chandram
Whole Time Director
(DIN : 00005868)





KAPOOR & PAREKH ASSOCIATES
CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on Review of Interim Consolidated Financial Results

To The Board of Directors of Wanbury Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Wanbury Limited (hereinafter referred to as the "the Parent" or "the Company") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended 30 June 2025 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the Parent and the following entities:

Subsidiaries:

- a) Wanbury Holding B.V
 - b) Ningxia Wanbury Fine Chemicals Company Limited
 - c) Wanbury Global FZE
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.





KAPOOR & PAREKH ASSOCIATES
CHARTERED ACCOUNTANTS

6. Other Matters:

- 6.1 Attention is drawn to the fact that the figures for the quarter ended 31 March 2025 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of the previous financial year had only been reviewed and not subjected to audit.
- 6.2 The Statement includes the interim financial results of three subsidiaries which have not been reviewed, whose interim financial results reflects total revenue of Rs. Nil, total net profit / loss after tax of Rs. Nil, total comprehensive income of Rs Nil, for the quarter ended 30 June 2025 respectively, as considered in the Statement.
According to the information and explanations given to us, these unaudited interim financial results, which have been approved and furnished to us by the management, are not material to the Group.
- 6.3 We have not reviewed the comparative consolidated financial information appearing in the statement of the corresponding quarter ended 30 June 2024.

The consolidated financial information of the Group for the corresponding quarter ended 30 June 2024 were reviewed by previous statutory auditors who issued their unmodified conclusion, vide their report dated 12 August 2024

Our conclusion is not modified in respect of matters specified in paragraph 6 above.

For Kapoor & Parekh Associates
Chartered Accountants
ICAI FRN 104803W


Ankit Parekh
Partner
M. No. 160398
UDIN: 251603988M0U201217



Mumbai, 04 August 2025



Wanbury Limited

Regd. Office : BSEL Tech Park, B-wing
10th Floor, Sector-30 A,
Opp. Vashi Railway Station,
Vashi Navi Mumbai 400 703
Maharashtra, INDIA
Tel : +91-22-6794 2222
+91-22-7196 3222
CIN L51900MH1988PLC048455
Email info@wanbury.com
Website www.wanbury.com

WANBURY LIMITED Statement of Unaudited Consolidated Financial Results for the Quarter ended 30 June 2025

Sr.No.	Particulars	(₹ in Lakhs)			
		Quarter ended			Year ended
		30/06/2025	31/03/2025	30/06/2024	31/03/2025
		Unaudited	Audited	Unaudited	Audited
1	Income:				
	(a) Revenue from operations	16,318.40	17,199.95	13,110.82	59,951.42
	(b) Other income	34.79	184.43	94.46	349.33
	Total Income	16,353.19	17,384.38	13,205.28	60,300.75
2	Expenses:				
	(a) Cost of materials consumed	7,278.41	7,594.54	6,419.91	27,788.20
	(b) Purchase of stock-in-trade	309.73	389.35	327.55	1,507.59
	(c) Changes in inventories of finished goods, work-in-progress and stock in trade	(53.58)	448.11	(121.98)	151.14
	(d) Employee benefits expense	2,868.64	2,642.14	2,515.16	10,423.76
	(e) Finance costs	754.03	904.24	759.26	3,695.07
	(f) Depreciation and amortisation expense	364.37	337.41	328.87	1,331.11
	(g) Other expenses	3,471.01	3,163.17	2,872.77	12,448.81
	Total Expenses	14,992.61	15,478.97	13,101.54	57,345.69
3	Profit before tax	1,360.58	1,905.41	103.74	2,955.07
4	Tax expenses :				
	(a) Current Tax	-	586.09	-	586.09
	(b) Deferred Tax(Net)	11.53	(706.33)	-	(684.03)
5	Profit after tax	1,349.05	2,025.64	103.74	3,053.01
6	Other comprehensive Income / (loss)				
	Items that will not be reclassified to profit or loss:				
	- Actuarial gain/ loss on defined benefit obligation	(24.30)	8.97	(27.26)	(54.84)
	Income tax effect on above	8.49	(3.14)	-	19.16
	Items that will be reclassified subsequently to profit or loss:				
	- The effective portion of gain and losses on hedging instruments in a cash flow hedge.	(8.70)	(1.80)	-	(1.80)
	Income tax effect on above	3.04	0.63	-	0.63
	Other comprehensive Income / (Loss) net of tax	(21.47)	4.66	(27.26)	(36.85)
7	Total comprehensive Income	1,327.58	2,030.30	76.48	3,016.16
8	Paid up Equity Share Capital (Face Value of ₹ 10 each)	3,287.70	3,277.05	3,274.55	3,277.05
9	Other Equity				2,650.13
10	Earnings per share of ₹ 10 each (not annualised for the quarter)				
	(1) Basic - ₹	4.12	6.18	0.32	9.32
	(2) Diluted - ₹	3.95	5.98	0.31	8.98

See accompanying notes to the financial results





Wanbury Limited

Regd. Office BSEL Tech Park, B-wing
10th Floor, Sector-30 A,
Opp. Vashi Railway Station,
Vashi Navi Mumbai 400 703
Maharashtra, INDIA
Tel : +91-22-6794 2222
+91-22-7196 3222
CIN L51900MH1988PLC048455
Email : info@wanbury.com
Website : www.wanbury.com

Statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2025

Notes :-

- 1) The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on 4 August 2025.
- 2) The consolidated financial results of Wanbury Limited or the Company or the Holding Company and its wholly owned subsidiaries (together referred to as "the Group") have been prepared as per Ind AS 110 on Consolidated Financial Statements. There is no minority interest.
- 3) These results are prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles, practices and policies generally accepted in India.
- 4) The Group has only one segment of activity namely "Pharmaceuticals".
- 5) The Holding Company has two USFDA approved manufacturing facilities i.e. Tanuku, Andhra Pradesh and Patalganga, Maharashtra.
- 6) During the quarter 1,06,500 equity shares of ₹ 10 each fully paid up, were allotted by the Holding Company upon exercise of vested options pursuant to the "Wanbury ESOP-2016", resulting in an increase in the paid-up share capital by ₹ 10.65 Lakhs and Securities Premium account by ₹ 144.31 Lakhs.
- 7) The figures for the fourth quarter ended 31 March 2025 in the above financial result are the balancing figures between audited figures for the full financial year and year to date unaudited figures published up to nine months ended 31 December 2024 which were subjected to limited review.
- 8) The figures of previous periods/year have been re-grouped / re-classified wherever necessary, to correspond with figures of the current period.

Place : Mumbai
Date: 4 August 2025


K. Chandran
Whole Time Director
(DIN : 00005868)

